146 related articles for article (PubMed ID: 35274714)
21. Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: Real-world data from 86 173 patients.
Takamori S; Shimokawa M; Komiya T
Thorac Cancer; 2021 Nov; 12(21):2943-2948. PubMed ID: 34612011
[TBL] [Abstract][Full Text] [Related]
22. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
[TBL] [Abstract][Full Text] [Related]
23. Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia.
Lu PH; Tsai TC; Chang JW; Deng ST; Cheng CY
J Clin Pharm Ther; 2021 Apr; 46(2):408-414. PubMed ID: 33332621
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors.
Guven DC; Sahin TK; Aksun MS; Taban H; Aktepe OH; Aksu NM; Akkaş M; Erman M; Kilickap S; Dizdar O; Aksoy S
Support Care Cancer; 2021 Apr; 29(4):2029-2035. PubMed ID: 32851486
[TBL] [Abstract][Full Text] [Related]
25. Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic.
Hijmering-Kappelle LBM; Hiltermann TJN; Bensch F
Clin Lung Cancer; 2022 Mar; 23(2):143-150. PubMed ID: 35034861
[TBL] [Abstract][Full Text] [Related]
26. Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
Vergnenegre A; Geier M; Guisier F; Lamy R; Comet B; Le Garff G; Do P; Janicot H; Morel H; Decroisette C; Andre M; Falchero L; Paleiron N; Monnet I;
Cancer Med; 2020 Jan; 9(2):432-439. PubMed ID: 31747137
[TBL] [Abstract][Full Text] [Related]
27. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.
Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H
Front Immunol; 2022; 13():968729. PubMed ID: 35967438
[TBL] [Abstract][Full Text] [Related]
28. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
29. Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.
Peyraud F; Guégan JP; Bodet D; Nafia I; Fontan L; Auzanneau C; Cousin S; Roubaud G; Cabart M; Chomy F; Le Loarer F; Chaput N; Danlos FX; Planchard D; Even C; Khettab M; Tselikas L; Besse B; Barlesi F; Soria JC; Marabelle A; Bessede A; Italiano A
Ann Oncol; 2022 Oct; 33(10):1041-1051. PubMed ID: 35850444
[TBL] [Abstract][Full Text] [Related]
30. Does immune checkpoint inhibitor increase the risks of poor outcomes in COVID-19-infected cancer patients? A systematic review and meta-analysis.
Lazarus G; Budiman RA; Rinaldi I
Cancer Immunol Immunother; 2022 Feb; 71(2):373-386. PubMed ID: 34173850
[TBL] [Abstract][Full Text] [Related]
31. Meta-Analysis of Quality of Life in Cancer Patients Treated With Immune Checkpoint Inhibitors.
Gonzalez BD; Eisel SL; Bowles KE; Hoogland AI; James BW; Small BJ; Sharpe S; Hyland KA; Bulls HW; Christy SM; Mansfield J; Nelson AM; Alla R; Maharaj K; Kennedy B; Lafranchise E; Williams NL; Jennewein S; Oswald LB; Postow MA; Dicker AP; Jim HSL
J Natl Cancer Inst; 2022 Jun; 114(6):808-818. PubMed ID: 34508604
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer.
Takahara Y; Tanaka T; Ishige Y; Shionoya I; Yamamura K; Sakuma T; Nishiki K; Nakase K; Nojiri M; Kato R; Shinomiya S; Fujimoto Y; Oikawa T; Mizuno S
Thorac Cancer; 2022 Feb; 13(4):624-630. PubMed ID: 34989146
[TBL] [Abstract][Full Text] [Related]
33. Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Qin A; Zhao S; Miah A; Wei L; Patel S; Johns A; Grogan M; Bertino EM; He K; Shields PG; Kalemkerian GP; Gadgeel SM; Ramnath N; Schneider BJ; Hassan KA; Szerlip N; Chopra Z; Journey S; Waninger J; Spakowicz D; Carbone DP; Presley CJ; Otterson GA; Green MD; Owen DH
J Natl Compr Canc Netw; 2021 Apr; 19(8):915-921. PubMed ID: 33878726
[TBL] [Abstract][Full Text] [Related]
34. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
35. Does prior exposure to immune checkpoint inhibitors treatment affect incidence and mortality of COVID-19 among the cancer patients: The systematic review and meta-analysis.
Liu Y; Liu S; Qin Y; Zhao L; Li Y; Zhou C; Chen W
Int Immunopharmacol; 2021 Dec; 101(Pt A):108242. PubMed ID: 34688136
[TBL] [Abstract][Full Text] [Related]
36. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
37. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
38. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint inhibitors in cancer patients with COVID-19.
Pan Y; Tan J; Li J; Li T; Li J; Cao Y; Yang L; Lin X; Li M; Liang X
Open Life Sci; 2023; 18(1):20220641. PubMed ID: 37426624
[TBL] [Abstract][Full Text] [Related]
40. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
Takamori S; Komiya T; Powell E
Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]